Enanta Pharmaceuticals | ENTA - Zobowiązania Handlowe





Zobowiązania Handlowe Zmiana Data
AbbVie USD 3.59B 28.65B 2025-12
Amgen USD 19.52B 1.37B 2026-03
Anika Therapeutics USD 6.34M 298K 2026-03
Arrowhead Research USD 32.94M 15.26M 2025-12
AstraZeneca USD 22.51B 2.78B 2026-03
BioCryst Pharmaceuticals USD 15.83M 10.26M 2025-12
Biogen USD 358.5M 73.5M 2026-03
Bristol-Myers Squibb USD 4.23B 659M 2026-03
Enanta Pharmaceuticals USD 1.88M 63K 2025-12
Gilead Sciences USD 715M 93M 2025-12
GlaxoSmithKline GBP 14.34B 1.05B 2026-03
Halozyme Therapeutics USD 20.9M 5.54M 2025-12
Heron Therapeutics USD 8.99M 3.02M 2025-12
Immunic USD 10.14M 2.22M 2025-12
Incyte USD 228.62M 1.41B 2026-03
Insmed USD 79.91M 316K 2025-12
Ionis Pharmaceuticals USD 26.03M 2.05M 2026-03
J&J USD 10.46B 1.53B 2026-03
Karyopharm Therapeutics USD 4M 1.39M 2025-12
Ligand Pharmaceuticals USD 3.24M 24.52M 2025-12
Merck USD 3.86B 541M 2026-03
Neurocrine Biosciences USD 545.5M 425.6M 2025-12
Novartis USD 4.32B 134M 2026-03
Novavax USD 24.58M 9.35M 2025-12
Pfizer USD 4.51B 734M 2026-03
PTC Therapeutics USD 45.49M 8.87M 2025-12
Roche Holding CHF 5.78B 1.27B 2025-12
Sarepta Therapeutics USD 280.84M 186.83M 2025-12
Vertex Pharmaceuticals USD 3.47B 40.6M 2026-03